For patients who have metastatic squamous non-small cell lung cancer (NSCLC) whose tumors were positive for EGFR copy number, as determined by the FISH analysis, survival tended to be better with the addition of necitumumab to their conventional chemotherapy.
Treatment with obinutuzumab in combination with bendamustine nearly doubled progression-free survival compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
The anti-PD-1 antibody pembrolizumab produced broad and durable responses in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Taking the vitamin B3 pill nicotinamide could reduce the risk of recurrence for those with a history of non-melanoma skin cancer.
Moving early to diagnose and treat lymphedema after breast cancer treatment can reverse this side effect or prevent it from becoming severe.
The risk of dying from prostate cancer increased fourfold when active surveillance was used to monitor men with intermediate-risk disease compared with low-risk prostate cancer patients, according to results of a new study, the first to examine long-term outcomes of patients with low- versus intermediate-risk prostate cancer who have been managed with this conservative approach to care.
Patients with newly diagnosed metastatic colorectal cancer (mCRC) who had higher levels of vitamin D in their blood lived a median of 8 months longer and experienced greater disease-free survival after their cancer treatment. This research was reported at a press briefing in advance of the 2015 Gastrointestinal Cancers Symposium.
Findings from a long-term analysis of the Women’s Intervention Nutrition Study (WINS) show that the deaths of women with hormone receptor–negative breast cancers were reduced by up to 54% when they followed a program to reduce their dietary fat intake.
Five years of tamoxifen continues to offer protection against breast cancer— reducing the risk of breast cancer by 29% in otherwise healthy women at high risk of the disease who have been followed now for 16 to 22 years.
Adding the investigational PI3K inhibitor pictilisib to fulvestrant in patients with metastatic breast cancer (MBC) yielded a doubling in progression-free survival (PFS) in women with both estrogen receptor (ER)– and progesterone receptor (PR)–positive disease.
Translating current and emerging knowledge of the molecular drivers of ovarian cancer is yielding promising new insights into potential clinical targets, moving treatment away from historical paradigms in favor of more personalized therapeutic approaches.
When Gail J. Roboz, MD, took the stage Wednesday to give her talk on what’s ahead in the treatment of acute myeloid leukemia (AML), she admitted feeling a little jealousy toward her colleagues in the lymphoid diseases.
The addition of the investigational hypoxia-targeted drug TH-302 to dexamethasone has demonstrated beneficial activity and a manageable adverse event profile in the treatment of patients with relapsed/refractory multiple myeloma.
Pembrolizumab continues to deliver impressive results in patients with advanced melanoma—producing long-lasting responses and improved overall survival, regardless of whether patients have been previously treated with ipilimumab.
The third-generation EGFR inhibitor CO-1686 continues to demonstrate promising activity in patients with non–small cell lung cancer (NSCLC) who developed resistance after prior treatment with an EGFR tyrosine kinase inhibitor (TKI).
Obesity significantly increases the risk of dying of breast cancer in premenopausal women with ER-positive early disease, according to findings from a large, retrospective study involving 80,000 patients.
The FDA’s Molecular and Clinical Genetics advisory committee has unanimously supported the safety, efficacy, and positive risk-benefit profile of the noninvasive stool-based DNA test Cologuard in a 10-0 vote.
The US Supreme Court’s landmark decision last June, mandating that an individual’s genes cannot be patented, transformed the genetic testing landscape and opened the marketplace to a host of new and complicated testing options.